Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-22 04:44:50 Source:politicsViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:UN Security Council rejects Russia
Next:Online reading or offline clubs? Young Chinese embrace both in digital era
You may also like
- Amal Clooney played key role in ICC bid to request arrest warrants for Israeli PM and Hamas leader
- Thailand welcomes 1st Chinese tour groups in 3 years
- China's Zhang makes history to reach 2nd round at Monte Carlo Masters
- Flowers make rural economy blossom
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East
- China's Zhang makes history to reach 2nd round at Monte Carlo Masters
- Migrating grey cranes fly to national wetland park in SW China's Yunnan to overwinter
- Wintering birds return to China's largest recovering freshwater lake
- Here comes the char